

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B45201	SERIAL NO. 10/088,632
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT D'Hondt, et al.	
		FILING DATE 30 July 2002	GROUP 1648

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No
MH		EP 0113 665	18-Jul-1984	EP				
		WO 95/22989	31-Aug-1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Boger, et al., "Subcutaneous and Intradermal Vaccination with Asian Influenza Vaccine," <i>J.A.M.A.</i> , 1957, 165(13):1687-1689.
		Couch, et al., "Improvement of Inactivated Influenza Virus Vaccines," <i>The Journal of Infectious Diseases</i> , 1997, 176:S38-S44.
		Hehme, N.W., "GSK's Pandemic Flu Vaccine Project: Evaluation of H2N2 and H9N2 Candidate Vaccines" GlaxoSmithKline Biologicals, <i>Who Meeting on Development and Evaluation of Influenza Pandemic Vaccines, Geneva</i> , 2005, pages 1-20.
		Kistner, et al., "Development of a Mammalian Cell (Vero) Derived Candidate Influenza Virus Vaccine," <i>Vaccine</i> , 1998, 16(9/10):960-968.
		Kistner, et al., "Development of a Vero Cell-Derived Influenza Whole Virus Vaccine," <i>Developments in Biological Standardization</i> , 1999, 98:101-110.
		La Montagne, et al., "Summary of Clinical Trials of Inactivated Influenza Vaccine," <i>Reviews of Infectious Diseases</i> , 1983, 5(4):723-736.
		Lin, et al., "Safety and Immunogenicity of an Inactivated Adjuvanted Whole-Virion Influenza A (H5N1) Vaccine: A Phase I Randomised Controlled Trial," <i>The Lancet</i> , 2006, 368:991-997.
		Merten, et al., "Production of Influenza Virus in Cell Cultures for Vaccine Preparation," <i>Advances in Experimental Medicine and Biology</i> , 1996, 397:141-151.
		Offit, et al., "Addressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?" <i>Pediatrics</i> , 2003, 112(6):1394-1401.
		Rinella, et al., "Effect of Anions on Model Aluminum-Adjuvant-Containing Vaccines," <i>Journal of Colloid and Interface Science</i> , 1995, 172:121-130.
		Seeber, et al., "Predicting the Absorption of Proteins by Aluminum-Containing Adjuvants," <i>Vaccine</i> , 1991, 9:201-203.
▼		Shirodkar, et al., "Aluminum Compounds Used as Adjuvants in Vaccines," <i>Pharmaceutical Research</i> , 1990, 7(12):1282-1288.

Serial No.: 10/088,632.
Group Art Unit No.: 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MH		Stephenson, <i>et al.</i> , "Development of Vaccines Against Influenza H5," <i>The Lancet</i> , 2006, 6:458-460.
		Stephenson, I., "H5N1 Vaccines: How Prepared are we for a Pandemic?" <i>The Lancet</i> , 2006, 368:965-966.
		White, <i>et al.</i> , Characterization of Aluminum-Containing Adjuvants," <i>Developmental Biology</i> , 2000, 103:217-228.
V		"Early Trial Show H5N1 Influenza Vaccine Safe and Effective in Humans at Low Doses," <i>The Lancet Press Release</i> , 2006.
EXAMINER	/Michelle Horning/	DATE CONSIDERED 02/01/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

n:\ej\h\appins\cases\b45201\pto1449-3.doc